Start Up

Located right in between Uppsala University, the Swedish Medical Products Agency, and Uppsala University Hospital, the company is well-positioned to exploit its pioneering discovery of a unique mesoporous magnesium carbonate (MMC) material. Up until breakthrough discovery by the group of Professor Maria Strømme in 2012, commercialized by Disruptive Materials AB in 2013, nobody had been able to produce an amorphous and anhydrous mesoporous magnesium carbonate with such high surface area and pore volume.

Disruptive Pharma at a glance

Disruptive Pharma is a pharmaceutical company utilizing its innovative MMC drug delivery technology to enable amorphous drug formulations. We aim to work with partners to turn their APIs into novel and commercially attractive drug products.

Disruptive Pharma provides the MMC technology and expertise for solving drug delivery problems. The company’s MMC technology is based on particulate amorphous mesoporous magnesium carbonate which offers competitive advantages over other technologies.

In addition, the company is developing its own pipeline of supergeneric/505(b)(2) products to address significant unmet medical and commercial needs. The lead product, an MMC improved sorafenib for treatment of HCC and RCC, will enter the clinic in the second half of 2024.

A Bright Future

By building a strategic a pipeline of proprietary formulations of oral small molecule drugs, primarily within the oncology area, we will showcase the MMC technology and bring MMC excipient to market. In this effort we offer various opportunities for partnerships and licensing agreements with both biotech and pharma companies.

We see a large potential in providing the best solutions for our partners to get the most out of their assets and turn them into commercially viable therapeutic drug products. The MMC technology can be used to extend and manage lifecycle of existing products based on crystalline formulation of drugs with poor water solubility. Our R&D team has established a streamlined process which reduces the effective development time for future products in our pipeline. The future looks bright!